{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:28:58Z","timestamp":1718238538281},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,12]]},"DOI":"10.7759\/cureus.62254","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T17:15:25Z","timestamp":1718212525000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Confusion in an Obese Patient Treated With Daptomycin: Neurotoxicity"],"prefix":"10.7759","author":[{"given":"Rova Malala Fandresena","family":"Randrianarisoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Raulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Merlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Tonnelier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Lise","family":"Lecapitaine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028021991943","article-title":"High-dose daptomycin and clinical applications","volume":"55","author":"Jones TW","year":"2021","unstructured":"Jones TW, Jun AH, Michal JL, Olney WJ. High-dose daptomycin and clinical applications. Ann Pharmacother. 2021, 55:1363-78. 10.1177\/1060028021991943","journal-title":"Ann Pharmacother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary M","year":"2018","unstructured":"Heidary M, Khosravi AD, Khoshnood S, Nasiri MJ, Soleimani S, Goudarzi M. Daptomycin. J Antimicrob Chemother. 2018, 73:1-11. 10.1093\/jac\/dkx349","journal-title":"J Antimicrob Chemother"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12743","article-title":"Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Lewis PO","year":"2018","unstructured":"Lewis PO, Heil EL, Covert KL, Cluck DB. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Pharm Ther. 2018, 43:614-25. 10.1111\/jcpt.12743","journal-title":"J Clin Pharm Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2016.04.022","article-title":"Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis","volume":"48","author":"Durante-Mangoni E","year":"2016","unstructured":"Durante-Mangoni E, Andini R, Parrella A, et al.. Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis. Int J Antimicrob Agents. 2016, 48:61-8. 10.1016\/j.ijantimicag.2016.04.022","journal-title":"Int J Antimicrob Agents"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia - a systematic review","volume":"5","author":"Uppal P","year":"2016","unstructured":"Uppal P, LaPlante KL, Gaitanis MM, Jankowich MD, Ward KE. Daptomycin-induced eosinophilic pneumonia - a systematic review. Antimicrob Resist Infect Control. 2016, 5:55. 10.1186\/s13756-016-0158-8","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phclin.2020.08.005","article-title":"Neurological impairment with daptomycin in a resuscitation patient: adverse drug reaction or misuse? A case report","volume":"56","author":"Durand A","year":"2021","unstructured":"Durand A, Cayeux S, Adehossi A, Richecoeur J, Schmit B. Neurological impairment with daptomycin in a resuscitation patient: adverse drug reaction or misuse? A case report. Pharm Hosp Clin. 2021, 56:87-90. 10.1016\/j.phclin.2020.08.005","journal-title":"Pharm Hosp Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8756932","article-title":"Daptomycin-induced posterior reversible encephalopathy syndrome (PRES)","volume":"2019","author":"Bitar De Zayas-Enriquez A","year":"2019","unstructured":"Bitar De Zayas-Enriquez A, Soper C. Daptomycin-induced posterior reversible encephalopathy syndrome (PRES). Case Rep Neurol Med. 2019, 2019:8756932. 10.1155\/2019\/8756932","journal-title":"Case Rep Neurol Med"},{"key":"ref8","unstructured":"Neuropsychiatric effect of daptomycin. (2021). Accessed. April 1, 2024: https:\/\/gme.ecu.edu\/wp-content\/pv-uploads\/sites\/162\/2021\/05\/F.-Afriyie-Neuropsychiatric-Effect-of-Daptomycin.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31486","article-title":"An update on treatment options for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: a systematic review","volume":"14","author":"Mahjabeen F","year":"2022","unstructured":"Mahjabeen F, Saha U, Mostafa MN, et al.. An update on treatment options for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: a systematic review. Cureus. 2022, 14:e31486. 10.7759\/cureus.31486","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26366","article-title":"Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines Group consensus statement","volume":"6","author":"McDonald EG","year":"2023","unstructured":"McDonald EG, Aggrey G, Tarik Aslan A, et al.. Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines Group consensus statement. JAMA Netw Open. 2023, 6:e2326366. 10.1001\/jamanetworkopen.2023.26366","journal-title":"JAMA Netw Open"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-016-0130-8","article-title":"Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE","volume":"15","author":"Seaton RA","year":"2016","unstructured":"Seaton RA, Gonzalez-Ruiz A, Cleveland KO, Couch KA, Pathan R, Hamed K. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob. 2016, 15:18. 10.1186\/s12941-016-0130-8","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12666","article-title":"Paralysis of the external popliteal sciatic nerve associated with daptomycin administration","volume":"43","author":"Villaverde Pi\u00f1eiro L","year":"2018","unstructured":"Villaverde Pi\u00f1eiro L, Rabu\u00f1al Rey R, Garc\u00eda Sabina A, Monte Secades R, Garc\u00eda Pais MJ. Paralysis of the external popliteal sciatic nerve associated with daptomycin administration. J Clin Pharm Ther. 2018, 43:578-80. 10.1111\/jcpt.12666","journal-title":"J Clin Pharm Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7399\/fh.11799","article-title":"Daptomycin associated myoclonus: a case report","volume":"46","author":"Scolari MJ","year":"2021","unstructured":"Scolari MJ, Pellegrini D. Daptomycin associated myoclonus: a case report. Farm Hosp. 2021, 46:40-2. 10.7399\/fh.11799","journal-title":"Farm Hosp"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00268-1","article-title":"Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Teng C","year":"2022","unstructured":"Teng C, Frei CR. Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drugs Real World Outcomes. 2022, 9:23-9. 10.1007\/s40801-021-00268-1","journal-title":"Drugs Real World Outcomes"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002455","article-title":"Antibiotic-associated encephalopathy","volume":"86","author":"Bhattacharyya S","year":"2016","unstructured":"Bhattacharyya S, Darby RR, Raibagkar P, Gonzalez Castro LN, Berkowitz AL. Antibiotic-associated encephalopathy. Neurology. 2016, 86:963-71. 10.1212\/WNL.0000000000002455","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S159587","article-title":"Safety of high-dose daptomycin in patients with severe renal impairment","volume":"14","author":"Tai CH","year":"2018","unstructured":"Tai CH, Shao CH, Chen CY, Lin SW, Wu CC. Safety of high-dose daptomycin in patients with severe renal impairment. Ther Clin Risk Manag. 2018, 14:493-9. 10.2147\/TCRM.S159587","journal-title":"Ther Clin Risk Manag"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt342","article-title":"Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment","volume":"69","author":"Chaves RL","year":"2014","unstructured":"Chaves RL, Chakraborty A, Benziger D, Tannenbaum S. Clinical and pharmacokinetic considerations for the use of daptomycin in patients with Staphylococcus aureus bacteraemia and severe renal impairment. J Antimicrob Chemother. 2014, 69:200-10. 10.1093\/jac\/dkt342","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.10.002","article-title":"Characterization of plasma daptomycin in patients with serum highly glycated albumin and obesity","volume":"29","author":"Miyadera Y","year":"2023","unstructured":"Miyadera Y, Yamada T, Imoto Y, Yagi T, Naito T, Kawakami J. Characterization of plasma daptomycin in patients with serum highly glycated albumin and obesity. J Infect Chemother. 2023, 29:119-25. 10.1016\/j.jiac.2022.10.002","journal-title":"J Infect Chemother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b22-00276","article-title":"Target therapeutic ranges of anti-MRSA drugs, linezolid, tedizolid and daptomycin, and the necessity of TDM","volume":"45","author":"Matsumoto K","year":"2022","unstructured":"Matsumoto K, Samura M, Tashiro S, et al.. Target therapeutic ranges of anti-MRSA drugs, linezolid, tedizolid and daptomycin, and the necessity of TDM. Biol Pharm Bull. 2022, 45:824-33. 10.1248\/bpb.b22-00276","journal-title":"Biol Pharm Bull"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/263626-a-case-of-confusion-in-an-obese-patient-treated-with-daptomycin-neurotoxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T17:15:30Z","timestamp":1718212530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/263626-a-case-of-confusion-in-an-obese-patient-treated-with-daptomycin-neurotoxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.62254","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}